Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER).

Drug Metab Dispos. 2003 Jul;31(7):815-32.

PMID:
12814957
2.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups.

J Clin Pharmacol. 2003 May;43(5):443-69. Review.

PMID:
12751267
3.

An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs.

Boddy AW, Snikeris FC, Kringle RO, Wei GC, Oppermann JA, Midha KK.

Pharm Res. 1995 Dec;12(12):1865-8.

PMID:
8786957

Supplemental Content

Loading ...
Support Center